Form 4: Oruka Therapeutics President Sells Shares
Insider Transaction (Form 4)
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 9,999 shares of common stock on July 13, 2026.
Summary
- Option exercise/conversion: acquired 8,541 Common Stock at $12.50 ($106,762) on July 13, 2026; holds 23,853 after (Direct).
- Option exercise/conversion: acquired 1,458 Common Stock at $34.39 ($50,141) on July 13, 2026; holds 25,311 after (Direct).
- Open-market sale: disposed of 300 Common Stock at $83.07 ($24,920) on July 13, 2026; holds 25,011 after (Direct).
- Open-market sale: disposed of 3,743 Common Stock at $84.26 ($315,369) on July 13, 2026; holds 21,268 after (Direct).
- Open-market sale: disposed of 5,656 Common Stock at $84.90 ($480,201) on July 13, 2026; holds 15,612 after (Direct).
- Open-market sale: disposed of 300 Common Stock at $85.63 ($25,690) on July 13, 2026; holds 15,312 after (Direct).
- Option exercise/conversion: disposed of 8,541 Employee Stock Option (right to buy) on July 13, 2026; holds 101,459 after (Direct).
- Option exercise/conversion: disposed of 1,458 Employee Stock Option (right to buy) on July 13, 2026; holds 61,250 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $846,180 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Arjun Agarwal — Officer (Senior Vice President, Finance)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-13 | Option exercise/conversion | Common Stock | 8,541 | $13 | $106.8K | 23,853 |
| 2026-07-13 | Option exercise/conversion | Common Stock | 1,458 | $34 | $50.1K | 25,311 |
| 2026-07-13 | Open-market sale | Common Stock | 300 | $83 | $24.9K | 25,011 |
| 2026-07-13 | Open-market sale | Common Stock | 3,743 | $84 | $315.4K | 21,268 |
| 2026-07-13 | Open-market sale | Common Stock | 5,656 | $85 | $480.2K | 15,612 |
| 2026-07-13 | Open-market sale | Common Stock | 300 | $86 | $25.7K | 15,312 |
| 2026-07-13 | Option exercise/conversion | Employee Stock Option (right to buy) | 8,541 | — | — | 101,459 |
| 2026-07-13 | Option exercise/conversion | Employee Stock Option (right to buy) | 1,458 | — | — | 61,250 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-13 | Option exercise/conversion (8,541 shares) |
| 2026-07-13 | Option exercise/conversion (1,458 shares) |
| 2026-07-13 | Open-market sale (300 shares) |
| 2026-07-13 | Open-market sale (3,743 shares) |
| 2026-07-13 | Open-market sale (5,656 shares) |
| 2026-07-13 | Open-market sale (300 shares) |
| 2026-07-13 | Option exercise/conversion (8,541 shares) |
| 2026-07-13 | Option exercise/conversion (1,458 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Arjun Agarwal
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.